A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

Trial Profile

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs Durvalumab (Primary) ; Mocetinostat (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mirati Therapeutics
  • Most Recent Events

    • 24 Apr 2018 According to a Mirati Therapeutics media release, 31 patients have been enrolled in this ongoing trial and the company plans to present more mature data at an oncology conference later this year.
    • 24 Apr 2018 Results (n=23; data cut-off date: 31 Mar 2018) of phase 2 in patients with NSCLC who have experienced documented disease progression following prior treatment with a checkpoint inhibitor, presented in an Mirati Therapeutics media release.
    • 06 Apr 2018 Planned End Date changed from 1 Oct 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top